Net Income

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

The neurohealth firm surpassed revenue estimates and hit positive cash flow, but a dynamic competitive landscape and CEO transition loom ahead of its earnings call.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

As Uni-Fuels blankets Thailand with bunkering services, the move highlights the nation's rising maritime importance and the intense battle for market share.

With burnout and financial woes plaguing healthcare, Altera Digital Health bets on advanced AI to ease burdens and restore the human touch at HIMSS26.

As AI reshapes software, Tricentis is taking its Transform conference global, pushing a new paradigm of 'agentic quality engineering.' Here's what it means.

L.E.K. Consulting's new report reveals fierce competition, faster trend cycles, and the widening gap between winners and losers in the apparel industry.

As shadow AI and autonomous agents create huge risks, Teramind's new platform offers total visibility to help firms innovate without sacrificing security.

As SIGA prepares to unveil its 2025 financials, investors are focused on the future of its Tpoxx contracts and its role in global biodefense strategy.

With promising clinical data for its heart disease treatments, Lexeo Therapeutics aims to capture investor attention at the upcoming Leerink conference.

In its first year post-Comcast, Versant Media battles linear TV declines with a bold digital pivot, a new dividend, and a $1 billion stock buyback.

A significant order for critical Tomahawk missile parts sends Mobix Labs' stock soaring, highlighting the firm's key role in a surging defense market.

Facing declining revenue, Goodfood adds restructuring and digital experts to its board. Can this shake-up revive the Canadian meal-kit pioneer?

A new report shows fraud fears in private credit are soaring, fueled by AI and bankruptcies, but data reveals a different story for secured lenders.

The digital asset giant is delisting from Toronto to streamline costs, a move that reshapes its buyback plan and how Canadian investors trade its stock.

Creality's new Sermoon P1 combines standalone processing and multi-mode lasers, offering industrial-grade 3D scanning at a disruptive price point.

A novel inhaled RNA therapy for a specific group of cystic fibrosis patients gains EMA fast-track status, promising accelerated access to new treatment.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

A new trial for a cell therapy targeting a rare eye disease offers hope, driven by a patient-advocate's journey and with potential to treat common AMD.